Gerald S. Werner, MD, FESC, FACC, FSCAI Klinikum Darmstadt GmbH

Slides:



Advertisements
Similar presentations
Is this the “spioenkop” for CABG?
Advertisements

Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany BSIC, Manchester, September 15, 2006.
Cardiology Morning Report: Revascularization in Stable Ischemic Heart Disease Bobby Mathew, MD LSU Internal Medicine, HO-II.
Coronary Revascularisation in Patients With Diabetes Mellitus Dr Rod Stables The Cardiothoracic Centre Liverpool UK.
Who needs a PCI in 2008…. Multivessel disease Dr Adrian Banning Consultant Cardiologist John Radcliffe Oxford.
Five-Year Follow-up of Safety and Efficacy of the Resolute Zotarolimus-Eluting Stent: Insights from the RESOLUTE Global Clinical Trial Program in Approximately.
2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.
CORONARY PRESSURE MEASURENT AND FRACTIONAL FLOW RESERVE
Ischemic heart disease. Indications and methods of surgical treatment. Surgery department №2.
Call for CASES Staged PCI in a patient with multivessel coronary disease disqualified from CABG. Pawel Buszman, MD, FESC, FSCAI Marcin Debinski, MD Krzysztof.
New ESC/EACTS guidelines on myocardial revascularisation Indications for coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention.
Myocardial Ischemia Redefined: Optimal Care in CAD.
New guidelines for CABG
1 1 The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National.
Management of Stable Angina SIGN 96
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Retrograde approach for the Recanalizaiton of Coronary CTO: Preliminary Experience of Single Centre Lei Ge, Juying Qian, Xuebo Liu, Qin Qing, Junbo Ge.
Name of the speaker: Germano DiSciascio I have the following potential conflicts of interest to report:  Consulting  Employment in industry  Stockholder.
Is the Decision-Making after Failure of CTO Angioplasty Same? Infarct Related CTO or Non- Infarct Related CTO (Continue the Procedure in Other Vessel or.
Multivessel Coronary Artery Disease
Ted Feldman MD, FACC, FESC, FSCAI Disclosure Information The following relationships exist: Grant support: Abbott, BSC, Edwards, St Jude, WL Gore Consultant:
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
End points in PTCA trials. A successful angioplasty is defined as the reduction of a minimum stenosis diameter to
Survival Benefits in Higher Risk Patients Coronary Revascularization has Revolutionized the Therapy of Ischemic Heart Disease Acute coronary syndromes.
Revascularization Strategy: Syntax Score and Beyond
Prognosis of Patients With LV Dysfunction and CAD
The OPTIMAX first-in-man study Mid-term clinical outcome of Titanium-Nitride-Oxide-coated Cobalt Chromium stents in patients with de novo coronary artery.
European Registry Update
Prof. Dr. med. Sigmund Silber Cardiology Practice and Hospital
A Randomized Multicentre Trial to Evaluate the Utilization of Revascularization or Optimal Medical Therapy for the Treatment of Chronic Total Coronary.
1-year Outcome of The Italian Registry on Chronic Total Occlusion:
Strategies to Improve Inadequate Guide Catheter Support
Multi Modality Approach to Diagnosis of Ischemia in Post CABG Cases
Clinical Usefulness of Post-Stenting FFR
Final Five-Year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients With Three-Vessel Disease and/or Left Main Disease Patrick.
Revascularization in Patients With Left Ventricular Dysfunction:
Complex Coronary intervention
CRT 2017 Interventional Challenging Case Anterior ST- Elevation Myocardial Infarction Resulting From Acute Occlusion of Left Internal Mammary Artery Graft.
Treating CTOs Is there evidence based data?
The Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel
In the name of God Presentation by: Dr. Isa Khaheshi
Meruzhan Saghatelyan, MD, Interventional cardiologist
A Randomized Multicentre Trial to Evaluate the Utilization of Revascularization or Optimal Medical Therapy for the Treatment of Chronic Total Coronary.
Coronary bifurcation wide-neck aneurysm successfully treated by provisional Y-stent-assisted coil embolization Gregory A. Sgueglia, MD, PhD Interventional.
The Winking Saphenous Vein Graft: Acute Aorto-Vein Graft Anastomotic Torsional Kink causing Dynamic Systolic Compression Complicating Vein Graft PCI Dr.
Radiation Management in Complex Procedures
Intra-Aortic Balloon Pump For Complex Calcified Left-Main Bifurcation Lesion Supawat Ratanapo, MD Medical College of Georgia, Augusta University.
Successful CTO PCI Associated with Lower Mortality Risk
On behalf of all principal COMPARE II investigators:
SYNTAX at 2 Years: This Interventionalist’s Perspective
Debate: What Does the Future Hold for the Treatment of Unprotected Left Main Disease? More PCI No More Routine Surgery Ron Waksman, MD, FACC Washington.
The Role of Interventional Treatment for The Failing Grafts
Interesting Case Review
On behalf of J. Belardi, M. Leon, L. Mauri,
Single Stage CABG and Peripheral Arterial Bypass for Combined Coronary and Peripheral Arterial Disease Divya Arora, Ashok Chahal and Shamsher Singh Lohchab.
The Guidelines Should Be Change!
The Hidden Cost of Underutilizing PCI for Chronic Total Occlusions
FINAL FIVE-YEAR CLINICAL OUTCOMES OF THE NOBORI2 TRIAL
STEMI-INITIAL PRESENTATION TIMING 2013 ACC/AHA GUIDELINES
Section 5: Intervention and drug therapy
Manesh R. Patel, MD, FACC, Gregory J
3-Year Clinical Outcomes From the RESOLUTE US Study
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
On behalf of all principal COMPARE II investigators:
O.L.Reuchlin gebruik van CT binnen de cardiogie
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
Presentation transcript:

Patient Selection for CTO Revascularization More than Just Symptom relief Gerald S. Werner, MD, FESC, FACC, FSCAI Klinikum Darmstadt GmbH Darmstadt, Germany

Potential conflicts of interest Speaker’s name: Gerald S. Werner  I have the following potential conflicts of interest to report:  Research contracts  Consulting  Employment in industry  Stockholder of a healthcare company  Owner of a healthcare company  Other(s)  I do not have any potential conflict of interest

A few facts on CTOs in daily practice Almost 20000 consecutive diagnostic angiographies in the Canadian CTO registry showed that in patients with significant CAD, 1 out of 5 lesions was a CTO (22%) : 32% of CTOs were in multivessel vessel disease Prior MI was reported in 41%, but only one third had ECG signs of prior MI Impaired LVEF was found in 50% of CTOs Only 17% underwent PCI of the CTO, only 2of 3 were successful Bradley Strauss et al. submitted

Patient Selection for PCI of CTOs To improve clinical symptoms Relief of angina and myocardial ischemia Relief of symptoms of heart failure To improve prognosis Efficacy as compared to CABG Patient and operator selection

Patient Selection for PCI of CTOs To improve clinical symptoms Relief of angina and myocardial ischemia Relief of symptoms of heart failure To improve prognosis Efficacy as compared to CABG Patient and operator selection

The ESC Guidelines and CTO-PCI Indication for revascularisation

Limited exercise capacity: 73 y, male

Collaterals do not prevent ischemia Ischemia no Ischemia Modified from Werner et al. Eur Heart J 2006;27:2406-12

Improved exercise capacity after CTO-PCI Baseline 12 month Maximum exercise 125 W 175 W Maximum heart rate 120 bpm 141 bpm Maximum oxygen uptake 20.8 ml/min/kg 28.8 ml/min/kg

MRI for patient selection with prior infarct Kirschbaum et al. Am J Cardiol 2008;101:179

Patient Selection for PCI of CTOs To improve clinical symptoms Relief of angina and myocardial ischemia Relief of symptoms of heart failure To improve prognosis Efficacy as compared to CABG Patient and operator selection

The ESC Guidelines and CTO-PCI Indication for revascularisation

Patient Selection for PCI of CTOs To improve clinical symptoms Relief of angina and myocardial ischemia Relief of symptoms of heart failure To improve prognosis Efficacy as compared to CABG Patient and operator selection

The ESC Guidelines and CTO-PCI Type of recommended revascularisation CTO target artery Galassi et al EuroIntervention. 2011 Aug;7(4):472-9

Recommended revascularisation: Impact of the SYNTAX score CABG PCI European Heart Journal (2010) 31, 2501–2555

The SYNTAX Score (www.syntaxscore.com) Only significant or occlusive lesions considered Multiplication factor based on level of stenosis: Total Occlusion x5 50-99% stenosis x2 + 4 Points based on CTO morphology + Points for Calcification Bifurcation Ostial location Diffuse disease Thrombus presence etc. 6 Points +6 +5 +3.5 +2.5 +1.5 +1 +0.5 Sianos et al EuroIntervention 2005;1:219-227

Total Occlusion Procedural characteristics CABG n=266 12 were not treated with CABG CABG n=254 Not Bypassed n=81 Bypassed n=173 Reason not bypassed: Not intended to treat (n=12) Diseased (n=11) Inadequate conduit (n=2) Too small (n=19) Unable to find (n=1) Other (n=36) Overall 68.1 % of TO were successfully bypassed ITT, Per Lesion

Procedural Characteristics Total Occlusion Subset: CABG RCT Patient-based CABG TO N=235 Off-pump surgery, % 17.0 Graft revascularization, % At least one arterial graft 97.8 Arterial graft to LAD 96.0 Double LIMA/RIMA 26.5 Complete arterial revascularization 20.6 Venous graft only 2.2 Grafts per patient, mean ± SD 2.8  0.7 Distal anastomosis/pt, mean ± SD 3.3  0.9 Complete Revascularization, % 49.6 Post-Proced. Hospital Stay, mean ± SD (d) 10.3  12.0 SYNTAX CTO Subset 27OCT08.doc exhibit 12 , 13 , 5 Site-reported data 18

Venous graft patency in CTOs About 75% of CTOs are located in the RCA or LCX PRAGUE IV. Circulation 2004;110:3418-3423

A 50 year old former soccer professional Reduced exercise capacity since may 2010 Moved from field position to goal keeping Ischemia detected by MRI collaterals SYNTAX Score 31.5

Total Occlusion Procedural characteristics PCI n=277 8 were not treated with PCI PCI n=269 The SYNTAX way to do PCI in CTOs is no option, however … Attempted to treat n=250 Not attempted n=19 Unsuccessful n=117 Successful n=133 Overall 49.4 % of TO successfully treated Per Lesion

Success rate and case load <40 / year 40-70 / year 70-100 / year >100 / year Galassi et al, EuroIngervention 2011;7:472-9

Advanced imaging tools improve outcome

MSCT reveals problem zone

Dear Surgeon …

… what would be the surgical outcome ?

PCI for CTO should be the primary option Revascularization of CTOs is the recommended strategy for symptomatic and ischemic patients based on studies and pathophysiologic findings The prognostic impact of a CTO is established in several clinical settings The complexity of the procedure requires expertise and experience Prevention of specific complications needs to be part of the procedural strategy

PCI for CTO should not be an option if... ...there is no viability in the myocardium subtended by the CTO (MRI required) ...there are severe additional lesions needing revascularization, when CABG is an option

Thank you ›› 4th Experts "Live" CTO Workshop 2012 Welcome to … September 20 - 21, 2012 London, UK www.eurocto.eu Course Director Carlo Di Mario London, UK Co-Directors Anthony Gershlick Leicester, UK David Hildick-Smith Brighton, UK Scientific Board Gerald S. Werner Darmstadt, Germany Nicolaus Reifart Bad Soden, Germany Alfredo R. Galassi Catania, Italy Hans Bonnier Brussels, Belgium George Sianos Thessaloniki, Greece Javier Escaned Madrid, Spain Thank you